Vertex and U.K. health officials have been arguing over pricing for Orkambi for so long that the drugmaker had to destroy nearly 8,000 packs that expired last year. More: Vertex destroys nearly 8,000 Orkambi packs amid U.K. pricing standoff Source:
read moreThe Trinity College spin-off has completed a £1.5-million funding round for its autoimmune treatments. More: New pharma Azadyne raises £1.5m for autoimmune disease treatment Source: News
read moreThe social prescription plan aims to bring about the major shift in perspective needed. More: NHS aims for one link worker per primary care network from July Source: News
read moreAstraZeneca’s PD-L1 inhibitor Imfinzi will be made available on the NHS in England immediately for patients with locally advanced unresectable non-small-cell lung cancer. More: AZ' Imfinzi to be funded for NHS use via CDF Source: News
read moreLatest data from NHS Digital shows an increase in the number of prescription items dispensed in the community, but a drop in their cost to the NHS. More: Number of prescription rises but cost falls again Source: News
read moreWeeks after a California jury hit Johnson & Johnson with a $29 million mesothelioma verdict, the company scored a win close to home. A jury in Middlesex County, New Jersey, cleared the drugmaker in a lawsuit brought by plaintiff Ricardo Rimondi alleging
read more© 1994 - 2026 B.M. Pharmaceuticals